Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women.
Thomas E BartlettIona EvansAllison JonesJames E BarrettShaun HaranDaniel ReiselKiriaki PapaikonomouLouise JonesChiara M S HerzogNora PashayanBruno M SimõesRobert B ClarkeD Gareth EvansTalayeh S GhezelayaghSakthivignesh Ponandai-SrinivasanNageswara R BoggavarapuParameswaran G LalitkumarSacha J HowellRosa Ana RisquesAngelique Flöter RådestadLouis DubeauKristina Gemzell-DanielssonMartin WidschwendterPublished in: Genome medicine (2022)
Clinical trial 1 Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial, clinicaltrialsregister.eu, 2009-009014-40 ; registered on 20 July 2009. Clinical trial 2 The effect of a progesterone receptor modulator on breast tissue in women with BRCA1 and 2 mutations, clinicaltrials.gov, NCT01898312 ; registered on 07 May 2013. Clinical trial 3 A pilot prevention study of the effects of the anti- progestin Ulipristal Acetate (UA) on surrogate markers of breast cancer risk, clinicaltrialsregister.eu, 2015-001587-19 ; registered on 15 July 2015.